Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma

被引:0
|
作者
Liu, Qiupng [1 ,2 ]
Li, Xiang [3 ]
Yang, Kailan [4 ,5 ]
Sun, Shuwen [1 ,2 ]
Xu, Xun [1 ,2 ]
Qu, Kai [6 ]
Xiao, Jiaqi [3 ]
Liu, Chenyue [3 ]
Yu, Hangqi [4 ,5 ]
Lu, Yinying [7 ,8 ]
Qu, Jinrong [4 ,5 ]
Zhang, Yudong [1 ,2 ]
Zhang, Yuelang [6 ]
机构
[1] Jiangsu Prov Hosp, Dept Hematol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Radiol, Xian, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Dept Radiol, Zhengzhou, Peoples R China
[5] Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Radiol, Xian, Peoples R China
[7] Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[8] Shenzhen Univ, Coll Life Sci & Oceanog, Guangdong Key Lab Plant Epigenet, Shenzhen, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; Liver tumor imaging staging; Disease prediction; Clinical decision support; MICROVASCULAR INVASION;
D O I
10.1007/s00261-024-04661-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background & aims The current staging system has limitations in preoperatively assessing hepatocellular carcinoma (HCC) and in precise detailed treatment allocation. This study aims to propose a new Liver Tumor Imaging Staging (LTIS) method for HCC. Methods 1295 patients who underwent CT or MRI and curative liver resection during January 2012 and October 2020 were retrospectively recruited from three independent institutions. All images were interpreted by two abdominal and a board-certified radiologist. LTIS was designed to discriminate low-grade (absence of microvascular invasion [MVI] and Edmondson-Steiner grade III/IV), intermediate (MVI + or Edmondson-Steiner grade III/IV but not both) and high-grade HCC (MVI + and Edmondson-Steiner grade III/IV) upon CT and MRI. Model was constructed in 578 derivation cohort (center 1) and validated in internal center 1 test cohort (n = 291), and external center 2 (n = 226) and center 3 (n = 200), respectively. Cronbach's alpha statistics were determined to assess interobserver agreement. Net clinical benefit of LTIS on recurrence-free survival (RFS) and overall survival (OS) was analyzed with a Cox proportional hazards model. Results LTIS shows good inter-reader agreements in both CT and MRI datasets, with a Cronbach's alpha coefficient of 0.86 and 0.85, respectively. In independent test, LTIS achieved agreement of 73.2% (281/384), 18.9% (100/528), and 69.2% (265/383) for determining low, intermediate, and high-grade HCCs with "ground truth" results. In the Cox analysis, LTIS was comparable to "ground truth" grade for predicting RFS (hazards ratio (HR), 1.30 vs. ground truth grade, 1.36 and 1.56) and OS (HR, 1.76 vs. ground truth grade, 2.00 and 3.03) of patients after surgery. In patients conventionally classified as having low-grade tumors (serum alpha-fetoprotein < 400 ng/mL, stage T1), 47.4% and 35.6% were reclassified as high-grade tumors upon LTIS restaging. The resulting LTIS subgroups showed a significant difference in RFS and OS at Kaplan-Meier analysis (Log-rank test, p < 0.001). Conclusion LTIS provides a potential noninvasive way to precisely stage HCC using CT and MRI.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Clinical Effect of Add-On Primovist-Enhanced Magnetic Resonance Imaging on Preoperative Tumor Staging in Hepatocellular Carcinoma Patients
    Jin, Young-Joo
    Lee, Jin-Woo
    Kwon, Oh Sang
    Jung, Young Kul
    Kwon, Jung Hyun
    Jang, Jeong Won
    Kim, Young Seok
    Kim, Tae Hun
    Jeon, Yong Sun
    JOURNAL OF SURGICAL ONCOLOGY, 2016, 114 (01) : 106 - 111
  • [32] Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
    Lee, Sung Uk
    Yoon, Sang Min
    Cheng, Jason Chia-Hsien
    Kim, Tae Hyun
    Kim, Bo Hyun
    Park, Jin-hong
    Jung, Jinhong
    Tsai, Chiao-Ling
    Chiang, Yun
    Park, Joong-Won
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [33] Imaging Accuracy of Hepatocellular Carcinoma (HCC) Staging in Cirrhotic Patients Undergoing Liver Transplantation
    Furlan, A.
    Almusa, O.
    Marsh, J. W.
    Federle, M. P.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2007, 188 (05)
  • [34] Preoperative staging of renal cell carcinoma using magnetic resonance imaging comparison with pathological staging
    Spero, Martina
    Brkljacic, Boris
    Kolaric, Branko
    Marotti, Miljenko
    CLINICAL IMAGING, 2010, 34 (06) : 441 - 447
  • [35] The impact of clinical versus pathological staging in oral cavity carcinoma-a multi-institutional analysis of survival
    Biron, Vincent L.
    O'Connell, Daniel A.
    Seikaly, Hadi
    JOURNAL OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2013, 42
  • [36] Liver transplantation for hepatocellular carcinoma: A 4-year prospective study validating expanded criteria based on preoperative staging
    Yao, FY
    Bass, NM
    Ascher, NL
    Roberts, JP
    HEPATOLOGY, 2005, 42 (04) : 197A - 197A
  • [37] A prospective study on down-staging of hepatocellular carcinoma prior to liver transplantation
    Yao, FY
    Hirose, R
    Bass, NM
    Davern, T
    Merriman, R
    Kerlan, RK
    Feng, S
    Freise, C
    Ascher, NL
    Roberts, JP
    GASTROENTEROLOGY, 2005, 128 (04) : A763 - A763
  • [38] MR imaging in the preoperative staging of breast carcinoma: Useful or riskful?
    Van Goethem, M
    Dykmans, L
    Buytaert, P
    van Dam, P
    De Schepper, A
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S70 - S70
  • [39] Preoperative Staging of Gallbladder Carcinoma Using Biliary MR Imaging
    Kim, Soo Jin
    Lee, Jeong Min
    Lee, Eun Sun
    Han, Joon Koo
    Choi, Byung Ihn
    JOURNAL OF MAGNETIC RESONANCE IMAGING, 2015, 41 (02) : 314 - 321
  • [40] Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
    Qiu, W-W.
    Zhong, Q.
    Wang, Z-K.
    Chen, Q-Y.
    Zheng, C-H.
    Li, P.
    Xie, J-W.
    Wang, J-B.
    Lin, J-X.
    Lu, J.
    Cao, L-L.
    Lin, M.
    Tu, R-H.
    Huang, Z-N.
    Lin, J-L.
    Zheng, H-L.
    Huang, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S1295 - S1295